3,5-Dihydroxy-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-6-heptenoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3,5-Dihydroxy-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-6-heptenoic acid
• 英文别名: (E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid
• 化学式: C₂₅H₂₄FNO₄
• 分子量: 421.5
• InChiKey: VGYFMXBACGZSIL-VAWYXSNFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  90.6
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof
  申请人：Satyanarayana Reddy Manne

  公开号：US20120016129A1

  公开（公告）日：2012-01-19

  Processes for preparing pravastatin, intermediates and pharmaceutically acceptable salts thereof are provided Crystalline forms of pravastatin, intermediates and pharmaceutically acceptable salts thereof are also disclosed.

  提供了制备普伐他汀、中间体和药用可接受盐的工艺。还公开了普伐他汀、中间体和药用可接受盐的结晶形式。
• [EN] POLYMORPHIC FORM OF PITAVASTATIN CALCIUM<br/>[FR] FORME POLYMORPHIQUE DE CALCIUM DE PITAVASTATINE
  申请人：FARMA GRS D O O

  公开号：WO2013037838A1

  公开（公告）日：2013-03-21

  The present invention relates to a new polymorphic form of pitavastatin calcium, a process for its preparation and a pharmaceutical composition comprising it. The new polymorphic form is characterized by an X-ray powder diffraction pattern as shown in Figure 1.

  本发明涉及一种匹伐他汀钙的新多形态形式，以及其制备方法和包含它的药物组合物。这种新多形态形式的特征是其X射线粉末衍射图谱如图1所示。
• METHOD FOR PRODUCING MEDICAMENTS CONTAINING HMG-COA-REDUCTASE INHIBITORS
  申请人：——

  公开号：US20020146454A1

  公开（公告）日：2002-10-10

  The invention relates to a process for producing medicaments which comprise HMG CoA reductase inhibitors in the form of their salts, characterized in that the corresponding precursors of the actual active compounds are converted with bases, which contain alkali metal or alkaline earth metal ions, in a solvent, into the active compound, and the resulting active compound-containing solution is processed into the desired administration form.

  本发明涉及一种制备药物的方法，所述药物包括以其盐的形式存在的HMG CoA还原酶抑制剂，其特征在于，将实际活性化合物的相应前体物与含有碱金属或碱土金属离子的碱基在溶剂中转化为活性化合物，并将得到的含有活性化合物的溶液加工成所需的给药形式。
• Rosuvastatin intermediates and process for the preparation of rosuvastatin
  申请人：Kansal Vinod Kumar

  公开号：US20090076292A1

  公开（公告）日：2009-03-19

  Provided are intermediates and process for the preparation of statins, preferably rosuvastatin.

  提供了制备他汀类药物（最好是罗伊司他）的中间体和过程。
• Processes for preparing calcium salt forms of statins
  申请人：Niddam-Hildesheim Valerie

  公开号：US20050197501A1

  公开（公告）日：2005-09-08

  Processes for preparing a calcium salt of a statin from an ester derivative or protected ester derivative of the statin by using calcium hydroxide are provided. The ester or protected ester derivative is contacted with calcium hydroxide to obtain the calcium salt. Preferred statins are rosuvastatin, pitavastatin and atorvastatin, simvastatin and lovastatin. In processes beginning with a protected statin ester derivative, the protecting group is hydrolyzed during salt formation by contact with calcium hydroxide, or is contacted with an acid catalyst followed by contact with calcium hydroxide.

  本发明提供了一种使用氢氧化钙从他汀的酯衍生物或保护酯衍生物制备钙盐的过程。将酯或保护酯衍生物与氢氧化钙接触，以获得钙盐。首选他汀是罗伊司他、匹伐他汀和阿托伐他汀、辛伐他汀和洛伐他汀。在以保护的他汀酯衍生物开始的过程中，保护基在与氢氧化钙接触时水解，在盐形成过程中，或与酸催化剂接触后再与氢氧化钙接触。